| 2023-05-15 |
详情>>
业绩披露：
2023年一季报每股收益-1.02美元,归母净利润-1386.85万美元,同比去年增长-22.17%
|
| 2023-04-28 |
详情>>
股本变动：
变动后总股本1445.97万股
|
| 2023-03-28 |
详情>>
业绩披露：
2022年年报每股收益-3.38美元,归母净利润-4376.64万美元,同比去年增长-19%
|
| 2022-11-08 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-2.46美元,归母净利润-3183.65万美元,同比去年增长-16.94%
|
| 2022-10-18 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2022-08-15 |
详情>>
业绩披露：
2022年中报每股收益-0.09美元,归母净利润-2248.18万美元,同比去年增长-64.29%
|
| 2022-08-02 |
股东大会：
将于2022-09-23召开股东大会
会议内容 ▼▲
- 1.To approve the potential issuance of shares of common stock underlying senior secured convertible notes in an amount that may be equal to or exceed 20% of common stock outstanding on June 30, 2022, for purposes of complying with Nasdaq Listing Rule 5635(d) (the "Nasdaq Proposal").
|
| 2022-06-21 |
复牌提示：
2022-06-21 07:55:59 停牌，复牌日期 2022-06-21 08:30:00
|
| 2022-05-16 |
详情>>
业绩披露：
2022年一季报每股收益-0.04美元,归母净利润-1135.17万美元,同比去年增长-109.01%
|
| 2022-05-13 |
股东大会：
将于2022-06-22召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors to serve three-year terms expiring at the 2025 Annual Meeting of Stockholders and until such director’s successor is elected and qualified, or until his earlier death, resignation or removal;
2.To approve an amendment to the amended and restated certificate of incorporation to effect a reverse stock split of the Company’s common stock, the decision whether to implement such split, being subject to the discretion of the Board of Directors (the “Reverse Stock Split Proposal”);
3.To approve the 9 Meters Biopharma, Inc. 2022 Stock Incentive Plan;
4.To hold an advisory (nonbinding) vote on named executive officer compensation;
5.To hold an advisory (nonbinding) vote on the frequency of future stockholder advisory votes on named executive officer compensation;
6.To ratify the appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.
|
| 2022-03-23 |
详情>>
业绩披露：
2021年年报每股收益-0.15美元,归母净利润-3677.94万美元,同比去年增长40.19%
|
| 2021-11-15 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.11美元,归母净利润-2722.44万美元,同比去年增长51.84%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-12 |
详情>>
业绩披露：
2021年中报每股收益-0.06美元,归母净利润-1368.42万美元,同比去年增长71.61%
|
| 2021-05-13 |
详情>>
业绩披露：
2021年一季报每股收益-0.03美元,归母净利润-543.11万美元,同比去年增长-50.74%
|
| 2021-05-12 |
股东大会：
将于2021-06-22召开股东大会
会议内容 ▼▲
- 1.Election of one Class III director to serve a three-year term expiring at the 2024 Annual Meeting of Stockholders and until such director’s successor is elected and qualified, or until his earlier death, resignation or removal;
2.Approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended (our “Charter”), to increase the number of authorized shares of common stock;
3.Ratification of the appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.
|
| 2021-03-22 |
详情>>
业绩披露：
2020年年报每股收益-0.58美元,归母净利润-6149.65万美元,同比去年增长-127.35%
|
| 2020-06-02 |
股东大会：
将于2020-06-30召开股东大会
会议内容 ▼▲
- 1.Elect two Class II directors each to serve a three-year term expiring at the 2023 Annual Meeting of Stockholders and one Class III director to serve a one-year term expiring at the 2021 Annual Meeting of Stockholders, and until each such director’s successor is elected and qualified, or until his earlier death, resignation or removal;
2.To authorize, for purposes of complying with Nasdaq Listing Rule 5635, the issuance of shares of our common stock upon the conversion of shares of our Series A preferred stock and related warrants (the “Nasdaq Proposal”);
3.To approve an amendment to the Company’s 2012 Omnibus Incentive Plan (the “2012 Plan”) to increase the shares reserved for issuance thereunder from 5,794,492 shares to 20,794,492 shares;
4.Ratification of the appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020.
|
| 2020-01-22 |
股东大会：
将于2020-02-14召开股东大会
会议内容 ▼▲
- 1.To authorize, for purposes of complying with Nasdaq Listing Rule 5635, the issuance of shares of our common stock, pursuant to the terms of that certain Agreement and Plan of Merger and Reorganization, dated October 6, 2019, by and among the Company, RDD Pharma Ltd and the other parties thereto, as amended by Amendment No. 1, dated December 17, 2019, in an amount in excess of 20% of our common stock outstanding before the issuance of such common stock (the “Merger Consideration Proposal”).
2.To approve the potential issuance of 20% or more of the Company’s issued and outstanding common stock pursuant to a proposed reduction in the exercise price of outstanding warrants (including an exchange of warrants for shares of common stock) (the “Warrants Proposal”).
3.To approve an amendment to the amended and restated certificate of incorporation to effect a reverse stock split of the Company’s common stock (the “Reverse Stock Split Proposal”).
|
| 2019-04-26 |
股东大会：
将于2019-05-31召开股东大会
会议内容 ▼▲
- 1.Elect two Class I directors to serve a three-year term expiring at the 2022 Annual Meeting of Stockholders, and until such director’s successor is elected and qualified, or until his earlier death, resignation or removal;
2.Ratification of the appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.
|
| 2018-10-16 |
股东大会：
将于2018-12-04召开股东大会
会议内容 ▼▲
- 1.Elect seven directors to serve a one-year term expiring at the 2019 Annual Meeting of Stockholders or, if Proposal 3 is approved, to hold office until the Annual Meeting of Stockholders applicable to the class of director to which the applicable director will be assigned, and until such director’s successor is elected and qualified, or until his or her earlier death, resignation or removal;
2.Approve an amendment to our 2012 Omnibus Incentive Plan (the “Plan”) to increase the number of shares authorized for issuance thereunder by 3,000,000 shares and implement an evergreen provision to automatically increase the total number of shares of common stock available under the Plan on an annual basis by a fixed percentage or such lesser amount as is determined by our board of directors;
3.Approve the proposed Amended and Restated Certificate of Incorporation (the “Restated Certificate”) to provide for a classified board of directors and grant to our board of directors the exclusive authority to fill vacancies on our board of directors;
4.Approve the Restated Certificate to require that special meetings of stockholders be called by (i) our board of directors, (ii) the chairperson of our board of directors, (iii) our chief executive officer or (iv) our president (our Amended and Restated Bylaws (our “Bylaws”) already contain a similar provision);
5.Approve the Restated Certificate to permit stockholder action only at a duly called annual or special meeting and to prohibit stockholder action by written consent or electronic transmission (our Bylaws already contain a similar provision, but it may be ineffective under Delaware law);
6.Contingent upon approval of Proposal 3, approve the Restated Certificate to prohibit director removal without cause and to allow removal with cause only by the vote of the holders of at least two-thirds of all then-outstanding shares of common stock of the Company;
7.Approve the Restated Certificate to grant to our board of directors the exclusive authority to increase or decrease the size of our board of directors (our Bylaws already contain a similar provision);
8.Approve the Restated Certificate to require a vote of the holders of at least two-thirds of all then-outstanding shares of common stock of the Company to amend certain provisions of the Restated Certificate and to amend our Bylaws;
9.Approve the Restated Certificate to conform certain provisions to Delaware law and to make various other clarifying and technical changes;
10.Ratify the appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.
|
| 2018-08-28 |
详情>>
内部人交易：
Laumas Sandeep等共交易3笔
|